Low Float (Nasdaq: NTRB) Has 5 Key Potential Catalysts (Analyst Target + Bullish Technicals)

Let's do a quick review...

*Sponsored by Nutriband Inc. Low Float (Nasdaq: NTRB) Has 5 Key Potential Catalysts (Analyst Target + Bullish Technicals)  July 2nd Greetings Readers, Let's do a quick review... Recently, we've had a few breakout ideas go absolutely berserk. Take my profile for March 31st. Unfolding a little bit slower than other breakout runners, that Nasdaq idea crushed a wild move since its alert. From a 3/31/25 open of $8.79, it has since established a new 52-week high of $38.25! That's a magical run of approximately 335%! How about my June 10th Nasdaq profile? All that one did was surge from an open of $2.70 on 6/10 to a high of $5.57 by June 25th. That's approximately 106%! And just last week, my most recent profile opened on Friday at $1.37 before running to a high of $2.43 on the day. That's an explosion of approx. 77% intraday! Ready for another profile to track closely? With a low float under 5Mn shares, an analyst $15 target suggesting significant upside potential, and a multitude of triggered technical indicators, you may want to consider this Nasdaq profile for your watchlist. Oh, and as I mentioned above, this little firecracker rattled off an incredible two-day move of $7.50+ in January after one of my alerts. Now, that's not to say any move will happen like that again, but with all the potential catalysts shared above, it might not hurt taking another look at: *Nutriband Inc. (Nasdaq: NTRB)* Nutriband is primarily engaged in the development of a portfolio of transdermal pharmaceutical products. Their lead product under development is an abuse-deterrent fent-a-nyl patch incorporating their AVERSA™ abuse-deterrent technology. AVERSA™ technology can be incorporated into any transdermal patch to prevent the abuse, misuse, diversion, and accidental exposure of drugs with abuse potential. And based on several potential breakout catalysts, NTRB has once again risen to the top spot on my watchlist: #1. A $15 Analyst Target Suggests Substantial Upside Potential! #2. A Low Float Could Create An Exceptionally Volatile Environment (Daily). #3. Multiple Triggered Technical Indicators May Suggest A Positive Outlook And Trend Confirmation. #4. Nutriband And Kindeva Successfully Complete Commercial Manufacturing For AVERSA. #5. Nutriband Receives U.S. Patent Securing Key IP Protection. But more on those in a second... Full Company Breakdown: Nutriband Inc. (Nasdaq: NTRB) Nutriband Inc. is a pharmaceutical company with a specific focus on transdermal technologies. Their model is to apply Transdermal Tech to existing FDA approved drugs with a goal to improve safety, efficacy, patient comfort and more. The company's first product and lead platform technology is AVERSA, an abuse deterrent tech which is applicable to any patch on the market today. According to Health Advances’ assessment and upon approval by the United States FDA, Aversa Fent-a-nyl is expected to reach peak annual sales of $200Mn. The company has 2 revenue generating subsidiaries, 4P Therapeutics and Pocono Pharmaceutical along with Active Intelligence which specializes in sports recovery products. Nutriband is earning revenues to keep their development burn at a minimum. They also own their own manufacturing and clinical development capabilities which drastically reduces their costs for AVERSA and other technologies. Furthermore, the company believes this technology has broad applicability to any therapeutic patch where deterring abuse and accidental misuse by children and pets are valuable attributes. AVERSA™ abuse deterrent transdermal technology incorporates aversive agents to prevent the Abuse, DiVERsion, MiSuse and Accidental exposure of drugs with abuse potential such as opioids Upon approval of AVERSA™ fent-a-nyl, the company expects that the FDA will consider requiring all fent-a-nyl patches be abuse deterrent as was required for all Oxy-con-tin generics Pipeline products include AVERSA™ buprenorphine and AVERSA™ meth-yl-phenidate According to Health Advances’ assessment and upon approval by the United States FDA, Aversa Fent-a-nyl will be priced competitively with generic fent-a-nyl patches and is expected to reach peak annual sales of $200Mn. If non-ADF transdermal fent-a-nyl products lose marketing approval, Aversa would have greater pricing flexibility and could generate >$800Mn in revenue. Aversa Pipeline Sources: NTRB Website. NTRB Presentation. ----- As mentioned above, NTRB has several potential catalysts that could create breakout buzz. Here's a few to consider now: #1. NTRB Potential Catalyst - A $15 Analyst Target Suggests Substantial Upside Potential! Back on June 20th, an analyst Noble Capital Markets suggested a new $15 target for NTRB. From NTRB's closing valuation this past Tuesday, that target suggested over 85% potential upside. Here's some key report highlights: Conclusion. We had projected the NDA filing in late 2H25 to 1H2026 and valued the company based on discounted EPS from FY2027, the first full year of sales. Our EPS projections also allowed for a st-ock offering to raise capital in 1Q25, which was not necessary. In view of our conservative time line and lower-than-expected share base, we are raising our FY2027 EPS estimate to $1.57 per share with a 25% discount rate for a new price target of $15 per share. ----- #2. NTRB Potential Catalyst - A Low Float Could Create An Exceptionally Volatile Environment (Daily). According to info from the Yahoo Finance website, NTRB has a pretty low float. The website reports this profile to have roughly 4.42Mn shares in its float. Why is that important? It's important on one crucial level. Volatility potential. If positive company news appears in the midway part of 2025, could it provide a breakout spark? ----- #3. NTRB Potential Catalyst - Multiple Triggered Technical Indicators May Suggest A Positive Outlook And Trend Confirmation. On Tuesday at 4:00PM EST, Barchart was reporting several triggered technical indicators across the short, medium, and long term for NTRB. Here's their list (as of 4:00PM EST Tuesday): Short Term Indicators 20 Day Moving Average 20 - 50 Day MA Crossover 20 - 100 Day MA Crossover 20 - 200 Day MA Crossover Medium Term Indicators 50 Day Moving Average 50 - 100 Day MA Crossover 50 - 150 Day MA Crossover 50 - 200 Day MA Crossover Long Term Indicators 100 Day Moving Average 150 Day Moving Average 200 Day Moving Average 100 - 200 Day MA Crossover The website also shares its all-important "Trend Seeker" composite indicator is triggered as well. Make sure to watch these technical indicators closely moving forward. ----- #4. NTRB Potential Catalyst - Nutriband And Kindeva Successfully Complete Commercial Manufacturing For AVERSA. Nutriband and Kindeva Complete Commercial Manufacturing Process Scale-up for Aversa™ Fent-a-nyl Abuse Deterrent Fent-a-nyl Patch Nutriband and Kindeva have completed commercial manufacturing process scale-up for its lead product Aversa™ Fent-a-nyl, an abuse-deterrent fent-a-nyl patch Nutriband is partnering with Kindeva to develop Aversa™ Fent-a-nyl which combines Nutriband’s Aversa™ abuse-deterrent technology with Kindeva’s FDA-approved fent-a-nyl patch ORLANDO, Fla., June 18, 2025 (GLOBE NEWSWIRE) -- Nutriband Inc. (NASDAQ:NTRB)(NASDAQ:NTRBW), a company engaged in the development of prescription transdermal pharmaceutical products, today announced that it has completed commercial manufacturing process scale-up for its lead product, Aversa™ Fent-a-nyl, with Kindeva, a leading global contract development and manufacturing organization (CDMO) focused on drug-device combination products. Nutriband is partnering with Kindeva to develop Aversa™ Fent-a-nyl which combines Nutriband’s Aversa™ abuse-deterrent technology with Kindeva’s FDA-approved fent-a-nyl patch. Aversa Fent-a-nyl is manufactured at Kindeva’s state-of-the-art transdermal manufacturing facility located in the United States. The next step is to manufacture clinical supplies and file an Investigational New Drug (IND) application with the FDA to initiate a human abuse liability clinical study. “We are excited to achieve this commercial development milestone with our partner, Kindeva. Completing the commercial manufacturing scale-up is an important step towards development of a commercially viable product and eventual NDA filing. This achievement demonstrates the compatibility of the Aversa™ abuse deterrent platform technology with established transdermal patch manufacturing processes. Aversa Fent-a-nyl has the potential to be the first abuse deterrent pain patch on the market,” said Gareth Sheridan, CEO, Nutriband. ... Read the full article here. ----- #5. NTRB Potential Catalyst - Nutriband Receives U.S. Patent Securing Key IP Protection. Nutriband Announces U.S. Patent Issued for Its Transdermal Abuse Deterrent Technology Patent issuance expands United States patent coverage for AVERSA™ transdermal abuse deterrent technology AVERSA™ transdermal abuse deterrent technology is protected by a broad international intellectual property portfolio with patents issued in 46 countries including the United States, Europe, Japan, Korea, Russia, China, Canada, Mexico, and Australia. ORLANDO, Fla., June 09, 2025 (GLOBE NEWSWIRE) -- Nutriband Inc. (NASDAQ:NTRB)(NASDAQ:NTRBW), a company engaged in the development of prescription transdermal pharmaceutical products, today announced that the United States Patent and Trademark Office (USPTO) issued patent number 12,318,492 on June 3, 2025, entitled "Abuse and Misuse Deterrent Transdermal Systems." The issuance of this patent further expands Nutriband’s intellectual property protection in the United States for its portfolio of abuse deterrent transdermal products based on its proprietary Aversa™ abuse deterrent technology. This technology can be incorporated into transdermal patches to prevent the abuse, diversion, misuse, and accidental exposure of drugs with abuse potential. ... Read the full article here. ----- (Nasdaq: NTRB) Potential Catalyst Recap - The Top 5 To Consider Right Now #1. A $15 Analyst Target Suggests Substantial Upside Potential! #2. A Low Float Could Create An Exceptionally Volatile Environment (Daily). #3. Multiple Triggered Technical Indicators May Suggest A Positive Outlook And Trend Confirmation. #4. Nutriband And Kindeva Successfully Complete Commercial Manufacturing For AVERSA. #5. Nutriband Receives U.S. Patent Securing Key IP Protection. ----- Coverage is officially reinitiated on Nutriband Inc. (Nasdaq: NTRB). I'll be in touch with updates when necessary. Talk again soon. Sincerely, Kai Parker StockWireNews (Always Remember The St-ock Prices Could Be Significantly Lower Now From The Dates I Provided.) *StockWireNews.com (“StockWireNews” or “SWN” ) is owned by SWN Media LLC, a single member limited liability company. Data is provided from third-party sources and SWN is not responsible for its accuracy. Make sure to always do your own research and due diligence on any day and swing profile SWN brings to your attention. Any emojis used do not have a specific defined meaning, and may be used inconsistently. We do not provide personalized in-vest-ment advice, are not in-vest-ment advisors, and any profiles we mention are not suitable for all in-vest-ors. Pursuant to an agreement between SWN Media LLC and TD Media LLC, SWN Media LLC has been hired for a period beginning on 07/02/2025 and ending on 07/03/2025 to publicly disseminate information about (NTRB:US) via digital communications. Under this agreement, SWN Media LLC has been paid seventeen thousand five hundred USD ("Funds"). To date, including under the previously described agreement, SWN Media LLC has been paid one hundred forty five thousand USD ("Funds"). These Funds were part of the funds that TD Media LLC received from Nutriband Inc., the issuer of (NTRB:US). Neither SWN Media LLC, TD Media LLC and their member own shares of (NTRB:US). Please see important disclosure information here: https://stockwirenews.com/disclosure/ntrb-kfqwn/#details

SWN Media | 160 W. Camino Real Unit 886 | Boca Raton, FL 33432 US Unsubscribe | Update Profile | Constant Contact Data Notice